Why the study?
Does long-term supplementation with marine omega-3 fatty acids (EPA-DHA) or vitamin D3 prevent incident atrial fibrillation in adults aged 50 years or older without prior cardiovascular disease?
Population
25,119 adults aged 50 years or older without prior cardiovascular disease, cancer, or atrial fibrillation…
Comparison
EPA-DHA and/or vitamin D3 administered long-term… vs Placebo
Design
RCT, 2 × 2 factorial randomized
Follow-up
median 5.3 years
Key result
Long-term administration of EPA-DHA or vitamin D3 did not significantly reduce incident atrial fibrillation compared with placebo (EPA-DHA HR 1.09, 95% CI 0.96-1.24, P=0.19).
Authors
Loading...
EPA-DHA or vitamin D3 should not be used to prevent incident AF; confirms lack of benefit in primary prevention among adults ≥50 years.
RCT (n=25,119)
2 × 2 factorial
Yes
Does long-term supplementation with marine omega-3 fatty acids (EPA-DHA) or vitamin D3 prevent incident atrial fibrillation in adults aged 50 years or older without prior cardiovascular disease?
Supplementation with marine omega-3 fatty acids or vitamin D3 does not significantly reduce the risk of incident atrial fibrillation in older adults without prior cardiovascular disease.
Effect estimate: HR 1.09 (95% CI 0.96-1.24)
Absolute Event Rate: 3.7% vs 3.4%
p-value: p=0.19
Albert et al. (2021) conducted an RCT in Atrial fibrillation (n=25,119). EPA-DHA and vitamin D3 vs. Placebo was evaluated on Incident AF confirmed by medical record review (HR 1.09, 95% CI 0.96-1.24, p=0.19). Long-term administration of EPA-DHA or vitamin D3 did not significantly reduce incident atrial fibrillation compared with placebo (EPA-DHA HR 1.09, 95% CI 0.96-1.24, P=0.19).